Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) EBITDA (2016 - 2025)

Historic EBITDA for Xtant Medical Holdings (XTNT) over the last 17 years, with Q3 2025 value amounting to $2.5 million.

  • Xtant Medical Holdings' EBITDA rose 16727.56% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 14533.18%. This contributed to the annual value of -$12.1 million for FY2024, which is 1886.2% down from last year.
  • According to the latest figures from Q3 2025, Xtant Medical Holdings' EBITDA is $2.5 million, which was up 16727.56% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Xtant Medical Holdings' EBITDA registered a high of $4.6 million during Q2 2025, and its lowest value of -$3.8 million during Q4 2023.
  • In the last 5 years, Xtant Medical Holdings' EBITDA had a median value of -$1.7 million in 2022 and averaged -$1.3 million.
  • As far as peak fluctuations go, Xtant Medical Holdings' EBITDA tumbled by 3652000.0% in 2022, and later skyrocketed by 25695.86% in 2025.
  • Xtant Medical Holdings' EBITDA (Quarter) stood at -$1.9 million in 2021, then grew by 9.79% to -$1.7 million in 2022, then plummeted by 120.77% to -$3.8 million in 2023, then skyrocketed by 50.55% to -$1.9 million in 2024, then soared by 235.02% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $4.6 million for Q2 2025, and $1.1 million during Q1 2025.